Jean-Michel Molina Selected Research

efavirenz (Sustiva)

1/2022	Brief Report: Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France.
1/2021	Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
1/2021	Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial.
2/2020	Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy.
1/2019	Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
1/2017	Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
3/2016	Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.
6/2014	Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
3/2013	Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.
3/2013	Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean-Michel Molina Research Topics

Disease

57	Infections 12/2022 - 04/2005
32	HIV Infections (HIV Infection) 01/2022 - 01/2003
14	Acquired Immunodeficiency Syndrome (AIDS) 01/2021 - 12/2003
11	Sexually Transmitted Diseases (Sexually Transmitted Disease) 10/2021 - 11/2005
10	Viremia 01/2022 - 11/2005
9	Coinfection 01/2022 - 04/2011
8	Tuberculosis (Tuberculoses) 01/2022 - 07/2008
7	Exanthema (Rash) 01/2021 - 11/2009
6	Nausea 01/2020 - 08/2008
6	Headache (Headaches) 01/2020 - 01/2014
6	Dizziness (Lightheadedness) 01/2019 - 07/2011
5	Chronic Hepatitis C 01/2017 - 07/2010
5	Lipodystrophy 01/2011 - 03/2002
5	Diarrhea 12/2007 - 06/2002
4	COVID-19 01/2022 - 12/2020
4	Microsporidiosis 01/2021 - 06/2002
4	Hepatitis B 09/2020 - 11/2015
4	Fibrosis (Cirrhosis) 03/2016 - 02/2006
4	Liver Cirrhosis (Hepatic Cirrhosis) 12/2015 - 02/2006
3	Inflammation (Inflammations) 03/2021 - 02/2020
3	Hepatitis 01/2019 - 04/2010
3	Immune Reconstitution Inflammatory Syndrome 03/2016 - 07/2008
2	Lymphoma (Lymphomas) 04/2022 - 12/2003
2	Communicable Diseases (Infectious Diseases) 01/2022 - 01/2020
2	Disease Progression 01/2022 - 01/2021
2	Syphilis 01/2020 - 11/2018
2	Glioblastoma (Glioblastoma Multiforme) 01/2019 - 06/2005
2	Neoplasms (Cancer) 01/2019 - 06/2010
2	Hepatitis C 01/2016 - 04/2011
2	Anemia 01/2016 - 12/2014
2	Renal Insufficiency (Renal Failure) 08/2013 - 04/2003
2	Malaria 03/2012 - 05/2008
2	Kaposi Sarcoma (Kaposi's Sarcoma) 01/2012 - 08/2005
2	Human Influenza (Influenza) 01/2012 - 07/2011
2	Hypersensitivity (Allergy) 05/2010 - 02/2008
2	Thrombocytopenia (Thrombopenia) 12/2009 - 06/2002

Drug/Important Bio-Agent (IBA)

27	RNA (Ribonucleic Acid)IBA 12/2022 - 04/2005
19	Tenofovir (Viread)FDA Link 01/2022 - 04/2003
19	Emtricitabine (Emtriva)FDA Link 10/2021 - 04/2005
15	efavirenz (Sustiva)FDA Link 01/2022 - 02/2006
15	Raltegravir Potassium FDA Link 01/2022 - 10/2009
14	Pharmaceutical PreparationsIBA 01/2022 - 05/2003
12	Ritonavir (Norvir)FDA Link 01/2020 - 04/2007
10	Antiviral Agents (Antivirals)IBA 01/2021 - 04/2005
9	NucleosidesIBA 01/2022 - 03/2002
9	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 05/2003
8	RacivirIBA 01/2022 - 05/2012
7	LipidsIBA 05/2022 - 01/2007
7	Ribavirin (Virazole)FDA LinkGeneric 01/2017 - 07/2010
6	Protease Inhibitors (Protease Inhibitor)IBA 01/2022 - 06/2005
6	Rilpivirine (TMC-278)IBA 09/2020 - 07/2011
6	tenofovir alafenamideIBA 01/2020 - 01/2017
6	Atazanavir Sulfate (Reyataz)FDA Link 03/2014 - 08/2008
5	Doxycycline (Periostat)FDA LinkGeneric 10/2021 - 03/2012
5	Lamivudine (Epivir)FDA Link 01/2021 - 06/2014
5	doravirineIBA 01/2021 - 01/2018
5	Darunavir (Prezista)FDA Link 01/2020 - 04/2007
4	Reverse Transcriptase InhibitorsIBA 01/2022 - 01/2007
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 06/2009
4	AntigensIBA 01/2021 - 01/2015
4	AntibodiesIBA 01/2021 - 05/2003
4	elvitegravirIBA 10/2019 - 04/2013
4	TabletsIBA 01/2019 - 03/2014
4	abacavir (Ziagen)FDA Link 01/2018 - 02/2008
4	InterferonsIBA 03/2015 - 07/2010
4	Enfuvirtide (Fuzeon)FDA Link 09/2011 - 10/2009
3	dolutegravirIBA 01/2022 - 04/2015
3	VaccinesIBA 12/2020 - 03/2012
3	Integrase InhibitorsIBA 02/2020 - 03/2011
3	CreatinineIBA 01/2020 - 04/2003
3	CobicistatIBA 10/2019 - 04/2013
3	daclatasvirIBA 01/2017 - 09/2015
3	Lopinavir FDA Link 01/2015 - 08/2008
3	HLA-B Antigens (HLA-B)IBA 09/2013 - 02/2008
3	Glucose (Dextrose)FDA LinkGeneric 01/2011 - 12/2003
2	Rifampin (Rifampicin)FDA LinkGeneric 01/2022 - 01/2021
2	IntegrasesIBA 01/2022 - 03/2011
2	EnzymesIBA 01/2021 - 01/2019
2	fumagillinIBA 01/2021 - 06/2002
2	cobicistat mixture with darunavirIBA 01/2019 - 01/2018
2	bictegravirIBA 01/2018 - 01/2018
2	Immunoglobulin G (IgG)IBA 03/2017 - 04/2012
2	SofosbuvirIBA 01/2017 - 03/2015
2	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 03/2016 - 01/2016
2	N- (8- aminohexyl)- 5- iodonaphthalene- 1- sulfonamide (W8)IBA 03/2016 - 01/2016
2	BilirubinIBA 01/2014 - 08/2008
2	HDL CholesterolIBA 01/2011 - 01/2007
2	etravirine (TMC-125)FDA Link 01/2010 - 11/2009

Therapy/Procedure

46	Therapeutics 01/2022 - 03/2002
14	Highly Active Antiretroviral Therapy (HAART) 03/2017 - 11/2005
6	Condoms (Condom) 11/2021 - 12/2015
5	Art Therapy 01/2022 - 01/2012
3	Hematopoietic Stem Cell Transplantation 01/2022 - 09/2007
3	Duration of Therapy 01/2022 - 07/2010
2	Stem Cell Transplantation 04/2022 - 09/2007
2	Aftercare (After-Treatment) 01/2022 - 01/2017
2	Transplantation 04/2021 - 04/2014
2	Injections 09/2020 - 04/2005
2	Drug Therapy (Chemotherapy) 04/2015 - 12/2003
2	Blood Transfusion (Blood Transfusions) 12/2014 - 11/2008